ImmuPharma (LON:IMM) Trading Up 27.3% - Time to Buy?

Key Points

• ImmuPharma's stock surged 27.3% during mid-day trading, reaching a high of GBX 12.75 ($0.17) after closing at GBX 9.90 ($0.13).
• The company reported a negative return on equity of 131.41% and a staggering net margin of 3,519.56% for the quarter ending August 6th.
• ImmuPharma focuses on peptide-based therapeutics, with its lead program, P140 (Lupuzor™), aimed at treating Lupus and potentially other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was up 27.3% during mid-day trading on Saturday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Price Performance

The stock has a market capitalization of £63.34 million, a price-to-earnings ratio of -1,415.73 and a beta of 1.53. The business has a 50 day simple moving average of GBX 7.92 and a 200-day simple moving average of GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.